Khaled Ezzedine
Prof Khaled Ezzedine is an expert in Dermatology at Hôpitaux Universitaires Henri-Mondor (France). As of October 2026, ScienceLeadR ranks Khaled Ezzedine in the top 1% of experts worldwide for Pigmentation Disorders, Syphilis and Sexually Transmitted Diseases. Khaled Ezzedine has authored 607 publications, the most recent in 2026, and is an investigator in 25 clinical trials, 11 of them ongoing. SLR score: 2,393 (community average: 125). How the SLR is computed.
LeadR Profile
Dermatology
Subspecialties: Public Health - Oncology - Infectiology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2006 - 2026
Number : 607
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Development of items to assess noticeability and sun sensitivity among patients with non-segmental vitiligo. PMID 42683533 — skin, quality of life, vitiligo, therapeutics | J Dermatolog Treat | 2026 | 0 |
| Cherry Angiomas in Individuals With Neurofibromatosis Type 1. PMID 42616496 — cells, neoplasms, skin diseases, odds ratio, prevalence, neurofibromatosis 1, sex, endothelial cells, neurofibromatoses | JAMA Dermatol | 2026 | 0 |
| Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies. PMID 42594914 — skin, safety, vitiligo, adolescent, herpes zoster, therapeutics | Lancet Top journal | 2026 | 3 |
| Work impact of immune-mediated inflammatory skin diseases: A systematic review and meta-analysis. PMID 42573445 — skin, sexually transmitted diseases, alopecia areata, sick leave, vitiligo, hidradenitis suppurativa, skin diseases, signs and symptoms, work, psoriasis, dermatitis, atopic | J Eur Acad Dermatol Venereol | 2026 | 0 |
| Healthcare Providers' Perspectives on Nonsegmental Vitiligo Severity, Patient Impact, and Treatment Gaps in the United States and Europe. PMID 42538872 — syphilis, safety, vitiligo, health personnel, therapeutics, steroids, wounds and injuries, dermatology | Br J Dermatol | 2026 | 1 |
Clinical Studies 25
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
11 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Long Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinical trials 2023-506548-18-00 — safety, dermatitis, dermatitis, atopic | Phase 2/Phase 3 | Not yet recruiting | 2022 |
| Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate to Severe Atopic Dermatitis 2023-508235-31-00 — safety, dermatitis, signs and symptoms, adolescent, therapeutics, dermatitis, atopic | Phase 3 | Active not recruiting | 2024 |
| A clinical trial to learn more about the effects of GIA632 in people with the most common type of vitiligo 2025-522301-37-00 — safety, vitiligo | Phase 2 | Recruiting | 2026 |
| Combination approach with ritlecitinib and nbUVB compared to ritlecitinib alone for treating vitiligo 2025-521504-22-00 — vitiligo | Phase 2 | Recruiting | 2025 |
| Vitiligo treatment by targeting TYK2 mediated responses 2023-507451-30-00 — vitiligo, therapeutics | Phase 2 | Active not recruiting | 2024 |
LeadR Networks
Main global connection map